An accurate reporting by Pfizer would have shown equal numbers of clinical trial deaths in the vaccine and placebo groups and thus, no benefit of vaccination.
To obtain emergency use authorization (EUA) for its COVID-19 vaccine, Pfizer and BioNTech submitted a data package in 2020 to the U.S. Food and Drug Administration (FDA) so the agency could evaluate the safety and efficacy of its vaccine. A recently published peer-reviewed study by the DailyClout Pfizer/BioNTech Documents Investigations Team suggests Pfizer excluded known deaths in the vaccine arm of its clinical trial from its data filing and withheld information from the agency that could have resulted in a denial of EUA.
Delayed reporting of the subject deaths into the Case Report Forms (CRFs) obscured the cardiac adverse event signal and allowed Pfizer/BioNTech’s request for EUA to proceed unchallenged, according to the study.
